drugset
drugset / Trial / NCT03599063

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

NCT03599063 ↗

Phase 1 Completed 63 enrolled Pfizer
RandomizedSequentialTriple-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06946860 in healthy adult subjects following single ascending doses This is the first clinical study of PF-06946860.

Timeline

Start
2018-07-30
Primary completion
2019-09-18
Completion
2019-09-18

Drugs

EvaluationDrugModalityDoseRoute
Subject ponsegromab Monoclonal antibody 0.1 mg Subcutaneous
Subject ponsegromab Monoclonal antibody 0.3 mg Subcutaneous
Subject ponsegromab Monoclonal antibody 1 mg Subcutaneous
Subject ponsegromab Monoclonal antibody 3 mg Subcutaneous
Subject ponsegromab Monoclonal antibody 10 mg Subcutaneous
Subject ponsegromab Monoclonal antibody 30 mg Subcutaneous
Subject ponsegromab Monoclonal antibody 100 mg Subcutaneous

Indications

No indication recorded.